Trade Cabaletta Bio, Inc. - CABA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0712 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Cabaletta Bio Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 15.9594 |
| Open* | 15.7294 |
| 1-Year Change* | 224% |
| Day's Range* | 15.1694 - 15.9894 |
| 52 wk Range | 3.22-19.34 |
| Average Volume (10 days) | 807.31K |
| Average Volume (3 months) | 16.73M |
| Market Cap | 755.01M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 42.85M |
| Revenue | N/A |
| EPS | -1.71 |
| Dividend (Yield %) | N/A |
| Beta | 2.49 |
| Next Earnings Date | Mar 14, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | 15.9594 | 0.4400 | 2.84% | 15.5194 | 16.0194 | 15.0194 |
| Nov 30, 2023 | 15.9694 | 1.7000 | 11.91% | 14.2694 | 16.1494 | 13.9994 |
| Nov 29, 2023 | 13.8394 | 0.3100 | 2.29% | 13.5294 | 15.6194 | 13.2794 |
| Nov 28, 2023 | 13.6594 | -4.7700 | -25.88% | 18.4294 | 18.7494 | 9.4894 |
| Nov 27, 2023 | 18.6294 | -0.0700 | -0.37% | 18.6994 | 19.0894 | 18.2994 |
| Nov 24, 2023 | 18.3194 | 0.1600 | 0.88% | 18.1594 | 18.9894 | 18.0094 |
| Nov 22, 2023 | 18.3894 | 1.0300 | 5.93% | 17.3594 | 18.6694 | 17.0594 |
| Nov 21, 2023 | 17.5994 | 0.4900 | 2.86% | 17.1094 | 18.2194 | 17.1094 |
| Nov 20, 2023 | 17.9294 | 0.0000 | 0.00% | 17.9294 | 18.3494 | 16.8694 |
| Nov 17, 2023 | 17.9194 | 0.7400 | 4.31% | 17.1794 | 18.0494 | 17.0394 |
| Nov 16, 2023 | 17.4094 | 0.1200 | 0.69% | 17.2894 | 17.4594 | 16.7294 |
| Nov 15, 2023 | 17.3394 | -0.2300 | -1.31% | 17.5694 | 18.3394 | 17.2094 |
| Nov 14, 2023 | 17.4394 | -0.6100 | -3.38% | 18.0494 | 18.2794 | 17.0894 |
| Nov 13, 2023 | 17.3694 | -0.1000 | -0.57% | 17.4694 | 17.7694 | 16.7294 |
| Nov 10, 2023 | 17.8894 | -0.0500 | -0.28% | 17.9394 | 18.7794 | 17.0694 |
| Nov 9, 2023 | 17.4494 | 0.2900 | 1.69% | 17.1594 | 18.4894 | 17.0494 |
| Nov 8, 2023 | 17.1494 | 0.8300 | 5.09% | 16.3194 | 18.1694 | 16.0894 |
| Nov 7, 2023 | 16.0494 | 0.7500 | 4.90% | 15.2994 | 16.3194 | 14.9694 |
| Nov 6, 2023 | 15.3094 | -0.6600 | -4.13% | 15.9694 | 16.0694 | 14.9694 |
| Nov 3, 2023 | 15.9594 | 0.3300 | 2.11% | 15.6294 | 16.3694 | 15.5094 |
Cabaletta Bio, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, March 14, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q4 2023 Cabaletta Bio Inc Earnings Release Q4 2023 Cabaletta Bio Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 54.139 | 46.313 | 33.833 | 18.683 | 6.193 |
| Selling/General/Admin. Expenses, Total | 14.839 | 13.819 | 12.457 | 7.012 | 1.726 |
| Research & Development | 39.3 | 32.494 | 21.376 | 11.671 | 4.467 |
| Operating Income | -54.139 | -46.313 | -33.833 | -18.683 | -6.193 |
| Interest Income (Expense), Net Non-Operating | 1.164 | 0.024 | 0.494 | 1.74 | 0.235 |
| Other, Net | 0 | -6.244 | |||
| Net Income Before Taxes | -52.975 | -46.289 | -33.339 | -16.943 | -12.202 |
| Net Income After Taxes | -52.975 | -46.289 | -33.339 | -16.943 | -12.202 |
| Net Income Before Extra. Items | -52.975 | -46.289 | -33.339 | -16.943 | -12.202 |
| Net Income | -52.975 | -46.289 | -33.339 | -16.943 | -12.202 |
| Income Available to Common Excl. Extra. Items | -52.975 | -46.289 | -33.339 | -22.269 | -12.202 |
| Income Available to Common Incl. Extra. Items | -52.975 | -46.289 | -33.339 | -22.269 | -12.202 |
| Diluted Net Income | -52.975 | -46.289 | -33.339 | -22.269 | -12.202 |
| Diluted Weighted Average Shares | 29.3429 | 25.7373 | 23.1452 | 24.034 | 22.5529 |
| Diluted EPS Excluding Extraordinary Items | -1.80538 | -1.79852 | -1.44043 | -0.92656 | -0.54104 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Diluted Normalized EPS | -1.80538 | -1.79852 | -1.44043 | -0.92656 | -0.54104 |
| Total Adjustments to Net Income | 0 | -5.326 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 15.89 | 16.956 | 16.302 | 11.778 | 13.06 |
| Selling/General/Admin. Expenses, Total | 4.093 | 4.521 | 3.902 | 3.562 | 3.546 |
| Research & Development | 11.797 | 12.435 | 12.4 | 8.216 | 9.514 |
| Operating Income | -15.89 | -16.956 | -16.302 | -11.778 | -13.06 |
| Interest Income (Expense), Net Non-Operating | 1.403 | 1.102 | 0.61 | 0.351 | 0.15 |
| Net Income Before Taxes | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Net Income After Taxes | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Net Income Before Extra. Items | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Net Income | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Income Available to Common Excl. Extra. Items | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Income Available to Common Incl. Extra. Items | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Diluted Net Income | -14.487 | -15.854 | -15.692 | -11.427 | -12.91 |
| Diluted Weighted Average Shares | 39.1728 | 35.4492 | 30.4136 | 29.014 | 28.9869 |
| Diluted EPS Excluding Extraordinary Items | -0.36982 | -0.44723 | -0.51595 | -0.39384 | -0.44537 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.36982 | -0.44723 | -0.51595 | -0.39384 | -0.44537 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 108.834 | 124.541 | 113.535 | 140.552 | 33.994 |
| Cash and Short Term Investments | 106.547 | 122.222 | 108.662 | 136.204 | 33.017 |
| Cash & Equivalents | 81.607 | 122.222 | 101.429 | 136.204 | 33.017 |
| Prepaid Expenses | 2.287 | 2.319 | 4.873 | 4.348 | 0.977 |
| Total Assets | 116.968 | 126.336 | 114.724 | 141.468 | 34.174 |
| Other Long Term Assets, Total | 0.565 | 0.357 | 0.299 | 0.101 | 0.18 |
| Total Current Liabilities | 9.489 | 8.38 | 5.18 | 3.147 | 0.943 |
| Accounts Payable | 2.463 | 2.333 | 1.243 | 0.92 | 0.603 |
| Accrued Expenses | 5.694 | 2.977 | 2.445 | 1.522 | 0.121 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.332 | 3.07 | 1.492 | 0.705 | 0.219 |
| Total Liabilities | 12.448 | 8.38 | 5.18 | 3.147 | 0.943 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 104.52 | 117.956 | 109.544 | 138.321 | 33.231 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 43.921 |
| Common Stock | 0.00029 | 0.00029 | 0.00024 | 0.00024 | 0 |
| Additional Paid-In Capital | 270.129 | 230.543 | 175.836 | 171.28 | 1.762 |
| Retained Earnings (Accumulated Deficit) | -165.562 | -112.587 | -66.298 | -32.959 | -12.452 |
| Total Liabilities & Shareholders’ Equity | 116.968 | 126.336 | 114.724 | 141.468 | 34.174 |
| Total Common Shares Outstanding | 29.4451 | 28.9271 | 24.0628 | 24.034 | 22.5529 |
| Property/Plant/Equipment, Total - Net | 7.569 | 1.438 | 0.89 | 0.815 | |
| Other Equity, Total | -0.04729 | -0.00029 | 0.00576 | -0.00024 | |
| Short Term Investments | 24.94 | 0 | 7.233 | ||
| Property/Plant/Equipment, Total - Gross | 9.938 | 2.629 | 1.348 | ||
| Accumulated Depreciation, Total | -2.369 | -1.191 | -0.458 | ||
| Other Liabilities, Total | 2.959 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 166.178 | 177.572 | 95.734 | 108.834 | 88.175 |
| Cash and Short Term Investments | 164.391 | 176.328 | 93.845 | 106.547 | 85.895 |
| Cash & Equivalents | 115.501 | 128.072 | 93.845 | 81.607 | 61.163 |
| Short Term Investments | 48.89 | 48.256 | 0 | 24.94 | 24.732 |
| Prepaid Expenses | 1.787 | 1.244 | 1.889 | 2.287 | 2.28 |
| Total Assets | 173.287 | 184.637 | 103.447 | 116.968 | 91.675 |
| Property/Plant/Equipment, Total - Net | 6.125 | 6.38 | 7.132 | 7.569 | 2.811 |
| Other Long Term Assets, Total | 0.984 | 0.685 | 0.581 | 0.565 | 0.689 |
| Total Current Liabilities | 10.616 | 8.482 | 9.305 | 9.489 | 5.801 |
| Accounts Payable | 3.62 | 2.341 | 3.955 | 2.463 | 1.333 |
| Accrued Expenses | 5.632 | 4.157 | 3.176 | 5.694 | 2.268 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.364 | 1.984 | 2.174 | 1.332 | 2.2 |
| Total Liabilities | 12.364 | 10.496 | 11.796 | 12.448 | 5.801 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 160.923 | 174.141 | 91.651 | 104.52 | 85.874 |
| Common Stock | 0.00042 | 0.00039 | 0.00031 | 0.00029 | 0.00029 |
| Additional Paid-In Capital | 373.295 | 370.047 | 273.067 | 270.129 | 235.953 |
| Retained Earnings (Accumulated Deficit) | -212.351 | -195.903 | -181.416 | -165.562 | -149.87 |
| Other Equity, Total | -0.02142 | -0.00339 | -0.00031 | -0.04729 | -0.20929 |
| Total Liabilities & Shareholders’ Equity | 173.287 | 184.637 | 103.447 | 116.968 | 91.675 |
| Total Common Shares Outstanding | 41.6602 | 39.7937 | 31.341 | 29.4451 | 29.014 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Other Liabilities, Total | 1.748 | 2.014 | 2.491 | 2.959 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -52.975 | -46.289 | -33.339 | -16.943 | -12.202 |
| Cash From Operating Activities | -46.38 | -34.109 | -26.77 | -16.045 | -4.661 |
| Non-Cash Items | 9.716 | 5.866 | 4.507 | 2.3 | 8.005 |
| Changes in Working Capital | -4.299 | 5.581 | 1.708 | -1.506 | -0.464 |
| Cash From Financing Activities | 32.982 | 48.903 | -0.024 | 119.925 | 37.677 |
| Issuance (Retirement) of Stock, Net | 32.982 | 48.903 | -0.024 | 119.925 | 37.677 |
| Net Change in Cash | -40.615 | 20.793 | -34.775 | 103.187 | 33.016 |
| Cash From Operating Activities | 1.178 | 0.733 | 0.354 | 0.104 | |
| Cash From Investing Activities | -27.217 | 5.999 | -7.981 | -0.693 | |
| Capital Expenditures | -2.453 | -1.166 | -0.635 | -0.693 | |
| Other Investing Cash Flow Items, Total | -24.764 | 7.165 | -7.346 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -15.854 | -52.975 | -37.283 | -25.856 | -12.946 |
| Cash From Operating Activities | -12.608 | -46.38 | -34.249 | -24.335 | -12.809 |
| Cash From Operating Activities | 0.365 | 1.178 | 0.82 | 0.457 | 0.219 |
| Non-Cash Items | 3.023 | 9.716 | 5.142 | 3.466 | 1.763 |
| Changes in Working Capital | -0.142 | -4.299 | -2.928 | -2.402 | -1.845 |
| Cash From Investing Activities | 24.62 | -27.217 | -26.901 | -50.809 | -49.911 |
| Capital Expenditures | -0.38 | -2.453 | -2.137 | -1.045 | -0.147 |
| Other Investing Cash Flow Items, Total | 25 | -24.764 | -24.764 | -49.764 | -49.764 |
| Cash From Financing Activities | 0.226 | 32.982 | 0.091 | 0.091 | 0.051 |
| Issuance (Retirement) of Stock, Net | 0.458 | 32.982 | 0.091 | 0.091 | 0.051 |
| Net Change in Cash | 12.238 | -40.615 | -61.059 | -75.053 | -62.669 |
| Financing Cash Flow Items | -0.232 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Fred Alger Management, LLC | Investment Advisor/Hedge Fund | 11.4882 | 4572886 | 557576 | 2023-06-30 | MED |
| Adage Capital Management, L.P. | Hedge Fund | 8.2066 | 3266645 | 725000 | 2023-06-30 | LOW |
| Commodore Capital LP | Hedge Fund | 5.9495 | 2368186 | 533186 | 2023-06-30 | MED |
| Deerfield Management Company, L.P. | Hedge Fund | 5.879 | 2340118 | 0 | 2023-06-30 | MED |
| Cormorant Asset Management, LP | Hedge Fund | 5.5816 | 2221739 | 400000 | 2023-06-30 | LOW |
| Lynx1 Capital Advisors LLC | Investment Advisor | 5.4802 | 2181377 | -273250 | 2023-06-30 | MED |
| Bain Capital Life Sciences Investors, LLC | Investment Advisor | 5.0245 | 2000000 | 0 | 2023-06-30 | LOW |
| VR Adviser, LLC | Venture Capital | 4.9573 | 1973251 | 0 | 2023-06-30 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.3249 | 1721512 | 607569 | 2023-06-30 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 4.0045 | 1594000 | 250000 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.9809 | 1584584 | 1363780 | 2023-06-30 | LOW |
| Perceptive Advisors LLC | Private Equity | 3.8814 | 1545000 | 820223 | 2023-06-30 | MED |
| Redmile Group, LLC | Investment Advisor/Hedge Fund | 3.4425 | 1370299 | 1096047 | 2023-06-30 | LOW |
| Nichtberger (Steven) | Individual Investor | 3.3902 | 1349483 | 0 | 2023-04-03 | LOW |
| Jennison Associates LLC | Investment Advisor/Hedge Fund | 2.9659 | 1180564 | 400000 | 2023-06-30 | LOW |
| Invesco Capital Management LLC | Investment Advisor | 2.1219 | 844621 | 844621 | 2023-06-30 | LOW |
| Boxer Capital, L.L.C. | Hedge Fund | 1.3566 | 540000 | 0 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.263 | 502727 | 282877 | 2023-06-30 | LOW |
| Blackstone Alternative Asset Management, L.P. | Investment Advisor/Hedge Fund | 1.2531 | 498779 | 498779 | 2023-06-30 | HIGH |
| TCG Crossover Management, LLC | Investment Advisor | 1.2229 | 486795 | 0 | 2023-06-30 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cabaletta Bio, Inc. Company profile
About Cabaletta Bio Inc
Cabaletta Bio Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company's lead CAAR T cell product candidate is designed based on chimeric antigen receptor (CAR), and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cabaletta Bio Inc revenues was not reported. Net loss increased 39% to $46.3M. Higher net loss reflects Research and development increase of 53% to $29.7M (expense), Stock-based Compensation in R&D increase of 38% to $2.7M (expense), General and administrative increase of 7% to $10.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.44 to -$1.80.
| Industry: | Bio Therapeutic Drugs |
2929 Arch Street
Suite 600
PHILADELPHIA
PENNSYLVANIA 19104
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com